Five things to know:
1. Medtronic’s revenue grew 4.1 percent year-over-year on an organic basis, according to a news release.
2. Cranial and spinal technologies raked in $1.1 billion, a 2.8 percent increase compared to the same time last year. Medtronic’s spine biologics saw low growth, and the neurosurgery segment saw high-single digit growth.
3. The robotics, navigation, imaging and powered surgical instruments segment saw double-digit growth year-over-year.
4. Medtronic’s cardiovascular portfolio brought in $2.8 billion, a 1 percent increase year-over-year.
5. The company increased its outlook for fiscal year 2023 and expects fourth quarter revenue growth of 4.5 percent to 5 percent.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
